TABLE 2

pKB values for antagonists at mutant or WT receptors

Data are presented as mean ± S.E.M. The values in parentheses represent the number of individual experiments performed.


Receptor

Agonist

Antagonist
sCT8-32
CGRP8-37
BIBN4096BS
WT AMY1(a) rAmy 7.78 ± 0.13 (11)e 6.62 ± 0.13 (11)e 7.44 ± 0.2 (7)
W74A AMY1(a) rAmy 7.48 ± 0.33 (3) 6.39 ± 0.48 (3) 6.50 ± 0.16 (3)*
W74K AMY1(a) rAmy 7.47 ± 0.24 (5) 6.15 ± 0.15 (5) 5.67 ± 0.18 (5)**
WT AMY1(a) hβCGRP 7.68 ± 0.18 (12)e 6.78 ± 0.13 (14)e 7.67 ± 0.17 (12)
W74A AMY1(a) hβCGRP 7.28 ± 0.29 (4) 6.25 ± 0.26 (4) 6.24 ± 0.32 (5)††
W74K AMY1(a) hβCGRP 7.86 ± 0.25 (3) 6.23 ± 0.56 (3) 6.25 ± 0.22 (3)††
WT AMY3(a) rAmy 7.92 ± 0.19 (6)e 6.17 ± 0.26 (7)e ≥ 5f (11)
E74W AMY3(a) rAmy 8.28 ± 0.16 (4) 5.85 ± 0.15 (4) 5.6 ± 0.12 (4)
WT CGRP1 hαCGRP 7.60 ± 0.44 (4) 10.14 ± 0.44 (3)
W74A CGRP1 hαCGRP 7.66 ± 0.30 (4) 8.59 ± 0.18 (4)a
W74K CGRP1 hαCGRP 8.02 ± 0.25 (4) 8.41 ± 0.24 (4)aa
WT CGRP1 hβCGRP 7.00 ± 0.43 (3) 9.73 ± 0.24 (3)
W74A CGRP1 hβCGRP 7.26 ± 0.35 (4) 8.45 ± 0.31 (4)bb
W74K CGRP1 hβCGRP 7.25 ± 0.25 (4) 7.49 ± 0.12 (4)bb
WT AM2 hAM 6.51 ± 0.06 (4) 6.39 ± 0.25 (4)
E74W AM2 hAM 6.14 ± 0.13 (3) 7.56 ± 0.11 (4)cc
WT AM2 hβCGRP 6.02 ± 0.38 (3) 6.29 ± 0.16 (4)
E74W AM2
hβCGRP

5.96 ± 0.23 (3)
7.35 ± 0.19 (3)d
  • *p < 0.05, **p < 0.01 versus WT AMY1(a) for rAmy with BIBN4096BS.

    ††p < 0.01 versus WT AMY1(a) for βCGRP with BIBN4096BS.

  • a p < 0.05, aap < 0.01 verus WT CGRP1 for hαCGRP with BIBN4096BS.

  • bb p < 0.01 versus WT CGRP1 for hβCGRP with BIBN4096BS.

  • cc p < 0.01 versus WT AM2 for hAM with BIBN4096BS.

  • d p < 0.05 versus WT AM2 for hβCGRP with BIBN4096BS, one-way ANOVA followed by Dunnett's multiple comparison test.

  • e Data from Hay et al. (2005); experiments were performed in parallel with this study.

  • f For 8 of 11 experiments, a pKB value could not be determined, but on three occasions, the pKB was equal to 5.4.